Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery

European Organisation for Research and Treatment of Cancer0 个研究点目标入组 908 人开始时间: 2005年2月17日最近更新: 2019年4月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 908

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•? Histologically proven diagnosis of GIST, with positive immunostaining for KIT (CD117)
•? Risk of relapse documented on the surgical specimen, according to the 2002 Consensus Approach to Diagnosis of GIST (See Appendix H and Ref. 7), as falling within the high-risk” category (tumor size >10 cm; or mitotic rate >10/50HPF; or tumor size >5 cm & mitotic rate >5/50HPF) or the intermediate-risk” category (tumor size <5 cm & mitotic rate 6-10/50HPF; or tumor size 5-10 cm & mitotic rate <5/50HPF).
•? Surgery performed from 2 weeks to 3 months before randomization (patients randomized in the treated arm should start Imatinib mesylate within 3 months of surgery).
•? Non evidence of residual macroscopic disease after surgery. Patients with R0 or R1 resection are eligible.
•? Prior surgery is admitted provided it was devoid of eradicative intent (e.g., surgery with a main diagnostic intent, emergency surgery with a symptomatic intent, etc.)
•? No prior radiation therapy, no prior chemotherapy for GIST, no prior therapy with Imatinib mesylate, or any other molecular targeted or biological therapy.
•? Absence of distant metastases, including absence of any peritoneal lesion not contiguous to the primary tumor, while regional positive lymph nodes are admitted provided they have been macroscopically excised.
•? Age >18 yrs.
•? WHO PS = 0-2 (see Appendix B)
•? The cardiac ejection function will be assessed at baseline. The choice of the method is left to physician’s discretion (LVEF (MUGA or ECHO), NT-proBNP….). An ECG must also be performed. No Class 3/4 cardiac problems, as defined by the New York Heart Association Criteria (e.g., congestive heart failure, myocardial infarction within 2 months of study; see Appendix C)
•? Absence of severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal disease, uncontrolled liver disease, including chronic viral hepatitis, judged at risk of reactivation, uncontrolled active infection, such as HIV infection, etc.).
•? No prior, or ongoing other malignancy, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or adequately treated cancer with eradicative intent for which the patient has been continuously disease-free for >5 years.
•? No ongoing pregnancy or nursing. Women/men of reproductive potential must agree to use an effective contraceptive method throughout the treatment period and for up to 3 months following discontinuation of the drug. Women of reproductive potential must have a negative pregnancy test within 7 days prior to treatment start.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

未提供

研究者

发起方

European Organisation for Research and Treatment of Cancer

相似试验

进行中（未招募）

1 期

EUCTR2004-001810-16-BEEuropean Organisation for Research and Treatment of Cancer900

进行中（未招募）

1 期

Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgeryGastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically, GIST cells are almost always positive for CD117.CD117 corresponds to the KIT receptor, a tyrosine kinase receptor which is altered in GIST due to a mutation to the c-kit oncogene. This event is held to be critical for GIST pathogenesis.MedDRA version: 14.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2004-001810-16-DEEuropean Organisation for Research and Treatment of Cancer900

进行中（未招募）

1 期

Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no furthrer therapy complete surgery. - EORTC 62024intermediate and high risk localized Gastrointestinal stromal tumors (GIST) patientsMedDRA version: 14.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2004-001810-16-ITITALIAN SARCOMA GROUP400

进行中（未招募）

1 期

Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgeryGastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically, GIST cells are almost always positive for CD117.CD117 corresponds to the KIT receptor, a tyrosine kinase receptor which is altered in GIST due to a mutation to the c-kit oncogene. This event is held to be critical for GIST pathogenesis.MedDRA version: 15.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2004-001810-16-DKEuropean Organisation for Research and Treatment of Cancer900

已完成

3 期

Adjuvant GIST Trial

ACTRN12605000712606AGITG400